Ugandan researchers and health officials have revealed ongoing plans to introduce long-acting injectable antiretroviral ...

Unlike daily PrEP, the injection is administered once every six months, offering continuous protection over that period.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...

Despite patients reporting preference for long-acting injectable antiretroviral therapy (LAI-ART), few patients with HIV report using LAI-ART.

The Food and Drug Administration (FDA) approved an injectable medication to be used as an HIV prevention drug on Wednesday. People would only need to use the drug every six months, or twice a year, ...

Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US Food and Drug Administration’s (FDA’s) approval of lenacapavir, according to a ...

The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission. Subscribe to ...

The FDA has approved Gilead Sciences’ lenacapavir, a twice-yearly injectable medication to prevent HIV, making it the first drug approved for adults and adolescents who are at risk. The FDA’s approval ...